The Power to Edit DNA: CRISPR-Cas9 and Sickle Cell Disease

In December 2020, the New England Journal of Medicine published a paper titled CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia, marking an exciting new chapter in the treatment of the disease

Join us as Dr. Jennifer Domm of the Sarah Cannon Research Institute at TriStar Centennial shares the story of how CRISPR-Cas9 gene editing was developed and describes how the technology has helped her treat an intractable, inherited, and painful blood disorder that affects some 100,000 Americans. Even after this treatment gained FDA approval for cell-based gene therapies for the treatment of sickle cell disease in 2023, there remain many barriers to commercial access. However, when it delivers a patient from the traumas of pain and frequent hospitalizations to a “normal” life it seems nothing short of miraculous.Register now for free to discover the promise of CRISPR Cas 9 that extends beyond medical treatment. It can also be used to study genetic functions or to develop pest and disease resistant agricultural products.

This ACS Webinar is moderated by Cheng Fang of Annovis Bio and is co-produced with SHI as part of the Joseph Priestley Society (JPS) series that promotes a deeper understanding of science, technology, and industry, with an emphasis on innovation and entrepreneurship.

What You Will Learn

• The history of how CRISPR became applicable to medicine
• The application of CRISPR-Cas9 to a debilitating and painful morbid disease, sickle cell anemia
• The science and data behind this therapy in patient trials